GLI2

Overview

GLI2 is a transcription factor and effector of Hedgehog (Hh) signaling. In PDAC, GLI2 alterations contribute to Hedgehog-pathway activation, which plays a role in tumor stroma and resistance to therapy.

Alterations observed in the corpus

  • Hedgehog-pathway alteration in PDAC (alongside GLI3, SMO, PTCH1, LRP2) PMID:25855536
  • Overexpressed in MAML3 fusion-positive pheochromocytoma/paraganglioma (PHC/PGNG) as part of the Wnt/Hedgehog pathway gene overexpression signature in the Wnt-altered mRNA subtype (TCGA PCPG study, n=173) PMID:28162975.
  • Targeted by recurrent fusion transcripts (structural rearrangements) in medulloblastoma in the ICGC/MAGIC 491-tumor WGS cohort; GLI2 rearrangements are listed as a recurrent SV target alongside PTEN and PVT1 PMID:28726821

Cancer types (linked)

  • PAAD: Hedgehog pathway alteration contributing to the landscape of actionable genomic lesions in PDAC PMID:25855536

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • Hedgehog-pathway alteration nominates Smoothened (SMO) inhibitors and downstream Hh pathway inhibitors as therapeutic candidates in PDAC PMID:25855536

Open questions

  • Specific alteration type (amplification/mutation) in GLI2 and whether Hh-pathway alterations predict response to SMO inhibitors in PDAC.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:28162975

This page was processed by wiki-cli on 2026-05-14. - PMID:28726821

This page was processed by wiki-cli on 2026-05-15.